

## Technology Appraisal Committee A Interests Register

**Topic: Mepolizumab for treating severe eosinophilic asthma [ID3750]**

**Publication Date: 03/02/2021**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alice Turner	TA Committee Member	Direct-financial	<ul style="list-style-type: none"> <li>Consultancy work for GSK about COPD, which is not the same as asthma but is a related airways disease.</li> <li>Recruited patients to competitor trials (Benraluzimab, AstraZeneca) in COPD.</li> </ul>	N/A	19/10/2020	N/A	It was agreed that this was a direct conflict which prevented Dr Turner from attending discussion on this topic.
Professor Ian Pavord	Clinical Expert	Direct – financial	<p>In the last 5 years:</p> <ul style="list-style-type: none"> <li>Received speaker's honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK</li> <li>Received payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva.</li> <li>Received honoraria for attending advisory panels with</li> </ul>	N/A	02/06/2020	N/A	It was agreed that these declarations would not prevent Professor Pavord from providing expert advice on this appraisal. He was not involved in decision making.

			<p>Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK.</p> <ul style="list-style-type: none"> <li>• Received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi.</li> <li>• Received a grant from Chiesi to support a phase 2 clinical trial in Oxford.</li> <li>• Co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed.</li> <li>• In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.</li> </ul>				
--	--	--	--	--	--	--	--